Survival with axicabtagene ciloleucel in large B-cell lymphoma
JR Westin, OO Oluwole, MJ Kersten… - … England Journal of …, 2023 - Mass Medical Soc
Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …
[HTML][HTML] Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American …
MA Perales, LD Anderson Jr, T Jain… - … and cellular therapy, 2022 - Elsevier
ABSTRACT Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …
Long‐term survivorship care after CAR‐T cell therapy
R Puckrin, K Jamani… - European Journal of …, 2024 - Wiley Online Library
While cytokine release syndrome and immune effector cell‐associated neurotoxicity
syndrome are well‐recognized acute toxicities of chimeric antigen receptor (CAR) T cell …
syndrome are well‐recognized acute toxicities of chimeric antigen receptor (CAR) T cell …
Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be
considered ineligible for curative-intent therapy including high-dose chemotherapy with …
considered ineligible for curative-intent therapy including high-dose chemotherapy with …
[PDF][PDF] Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
COI notes: Competing interests: RB reports consulting: BMS, Caribou Biosciences,
Genentech, Janssen, Pfizer, Sanofi, SparkCures; Research: Novartis, Pack Health. CP …
Genentech, Janssen, Pfizer, Sanofi, SparkCures; Research: Novartis, Pack Health. CP …
Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy
PC Johnson, T Dhawale, RA Newcomb… - Blood …, 2023 - ashpublications.org
Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment for
relapsed/refractory hematologic malignancies; however, data on patient-reported outcomes …
relapsed/refractory hematologic malignancies; however, data on patient-reported outcomes …
[HTML][HTML] Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review
F Efficace, L Cannella, F Sparano, JM Giesinger… - …, 2022 - journals.lww.com
The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
P Dreger, P Corradini, JG Gribben, B Glass… - The Lancet …, 2023 - thelancet.com
The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the
second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected …
second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected …
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-
cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel …
cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel …
Prognostic value of 18F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
L Michaud, K Bantilan, A Mauguen… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Early identification of patients with diffuse large B-cell lymphoma (DLBCL) who are likely to
experience disease recurrence or refractory disease after rituximab plus cyclophosphamide …
experience disease recurrence or refractory disease after rituximab plus cyclophosphamide …